# Kura Oncology Fundamentals

KURA | Stock | ## USD 16.00 0.43 2.76% |

Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Oncology Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kura Oncology | Select Account or Indicator |

**M**, whereas Consolidated Income is forecasted to decline to (133.9

**M**).

## Kura Oncology Current Liabilities Analysis

Kura Oncology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.## Kura Oncology Current Liabilities | ## 24.23 Million |

Current Liabilities | = | Payables | + | Accrued Debt |

## Current Kura Oncology Current Liabilities | 5.05 M |

Most of Kura Oncology's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Kura Oncology Current Liabilities Historical Pattern

Today, most investors in Kura Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kura Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kura Oncology current liabilities as a starting point in their analysis.

Kura Oncology Current Liabilities |

Share

Timeline |

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Compare to competition |

## Kura Oncology Total Liabilities

## Total Liabilities | ## 29.61 Million |

In accordance with the recently published financial statements, Kura Oncology has a Current Liabilities of 5.05

**M**. This is 99.71% lower than that of the Biotechnology sector and 99.07% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.94% higher than that of the company.## Kura Oncology Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kura Oncology's current stock value. Our valuation model uses many indicators to compare Kura Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kura Oncology competition to find correlations between indicators driving Kura Oncology's intrinsic value. More Info.Kura Oncology is rated**second**overall in current valuation category among related companies. It is rated

**fourth**overall in debt to equity category among related companies . The ratio of Current Valuation to Debt to Equity for Kura Oncology is about 43,976,769,462 . The current year Long Term Debt to Equity is expected to grow to 0.008212. The current year Debt to Equity Ratio is expected to grow to 0.014. Comparative valuation analysis is a catch-all model that can be used if you cannot value Kura Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kura Oncology's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kura Oncology's earnings, one of the primary drivers of an investment's value.

## Kura Oncology Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in current valuation category among related companies.

## Kura Oncology Current Valuation Drivers

We derive many important indicators used in calculating different scores of Kura Oncology from analyzing Kura Oncology's financial statements. These drivers represent accounts that assess Kura Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kura Oncology's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (1.11 M) | (1.31 M) | (1.05 M) | (1 M) | (1.08 M) | (1.16 M) | |

Average Assets | 79.18 M | 161.24 M | 232.97 M | 391.56 M | 575.09 M | 620.49 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (35.27 M) | (62.64 M) | (68.34 M) | (91.65 M) | (130.66 M) | (134.1 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (34.52 M) | (59.47 M) | (62.56 M) | (88.85 M) | (129.49 M) | (132.9 M) | |

Earnings before Tax | (35.43 M) | (60.45 M) | (63.14 M) | (89.62 M) | (130.47 M) | (133.9 M) | |

Average Equity | 65.74 M | 143.2 M | 212.13 M | 360.74 M | 546.23 M | 589.35 M | |

Enterprise Value | 446 M | 519.74 M | 575.83 M | 1.79 B | 897.49 M | 846.4 M | |

Free Cash Flow | (28.44 M) | (48.66 M) | (54.76 M) | (72 M) | (105.7 M) | (108.48 M) | |

Invested Capital | 81.48 M | 160.15 M | 207.77 M | 308.37 M | 427.59 M | 461.35 M | |

Invested Capital Average | 65.3 M | 135.38 M | 172.27 M | 240.25 M | 489.37 M | 528 M | |

Market Capitalization | 462.3 M | 534.04 M | 623.08 M | 1.85 B | 931.78 M | 879.87 M | |

Tangible Asset Value | 95.85 M | 182.38 M | 241.97 M | 647.21 M | 534.05 M | 434.79 M | |

Working Capital | 84.61 M | 167.58 M | 224.04 M | 611.27 M | 499.83 M | 406.36 M |

## Kura Oncology Fundamentals

Return On Equity | (0.28) % | |||

Return On Asset | (0.17) % | |||

Current Valuation | 571.7 M | |||

Shares Outstanding | 66.9 M | |||

Shares Owned by Insiders | 2.70 % | |||

Shares Owned by Institutions | 97.30 % | |||

Number of Shares Shorted | 6.98 M | |||

Price to Earning | (9.03) X | |||

Price to Book | 2.37 X | |||

EBITDA | (129.49 M) | |||

Net Income | (130.47 M) | |||

Cash and Equivalents | 450.26 M | |||

Cash per Share | 6.73 X | |||

Total Debt | 5.89 M | |||

Debt to Equity | 0.013 % | |||

Current Ratio | 25.73 X | |||

Book Value Per Share | 6.27 X | |||

Cash Flow from Operations | (104.55 M) | |||

Short Ratio | 5.67 X | |||

Earnings Per Share | (1.99) X | |||

Target Price | 28.67 | |||

Number of Employees | 127 | |||

Beta | 0.85 | |||

Market Capitalization | 1.03 B | |||

Total Asset | 534.05 M | |||

Retained Earnings | (218.48 M) | |||

Working Capital | 81.81 M | |||

Current Asset | 86.87 M | |||

Current Liabilities | 5.05 M | |||

Z Score | 94.1 | |||

Net Asset | 534.05 M |

## About Kura Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.
## Kura Oncology Investors Sentiment

The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura Oncology. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Kura Oncology's public news can be used to forecast risks associated with investment in Kura Oncology. The trend in average sentiment can be used to explain how an investor holding Kura Oncology can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kura Oncology using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

## Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go | |

Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | Go | |

Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum | Go | |

Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | Go | |

Focused OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences | Go | |

Probability Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years | Go |

Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 1 B | Return On Assets (0.17) | Return On Equity (0.28) |

The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.